



CERVICAL CORD ATROPHY AND DIFFUSION TENSOR IMAGING IN MOGAD, AQP4-AB NMOSD AND MS

Romina Mariano¹, Silvia Messina¹, Adriana Roca-Fernandez¹, Ana Cavey¹, Rosie Everett², Sandra Reeve², Maria Isabel Leite¹, Yazhuo Kong^{1,3}, Jacqueline Palace¹
¹Nuffield Department of Clinical Neurosciences, University of Oxford, ²Oxford University Hospitals NHS Trust, ³The Key Laboratory of Behaviour Science, Institute of Psychology, Chinese Academy of Sciences



BACKGROUND & AIM

- Spinal cord involvement is an important feature of antibody-mediated demyelination, as occurs in myelin-oligodendrocyte glycoprotein antibody disease (MOGAD) and aquaporin-4 (AQP4-Ab)-positive neuromyelitis optica spectrum disorder (NMOSD), as well as in multiple sclerosis (MS).
- Cervical cord MRI metrics are emerging as an important outcome measure in MS but their application in AQP4-Ab-positive NMOSD and MOGAD are not well studied.
- We aim to compare cervical cord atrophy and diffusion measurements between these conditions and also to healthy volunteers (HV) and to explore their clinical relevance.

METHODS

- Adult patients with spinal cord involvement and either relapsing remitting MS (n = 20), AQP4-Ab NMOSD (n = 20) or MOGAD (n = 20) were recruited at least six months outside of a relapse.
- Clinical details were collected and an Expanded Disability Status Scale (EDSS), Brief Pain Inventory and cervical cord 3T MRI (3DT1, 3DT2, axial T2*, diffusion) were done under the appropriate ethics. Matched HV (n = 20) underwent the same MRI scan.
- T2w scans were used for lesion location segmentation using FSL. T1w scans were used to calculate the mean cervical cord cross-sectional area (CSA) across C1-C7 using SCT (v.4.0). Diffusion imaging was pre-processed using FSL *topup* and *eddy*, followed by registration and metric extraction using SCT.

RESULTS

DEMOGRAPHICS & IMAGING ANALYSIS

Table 1. Demographics

	MOG	AQP4	MS	HV
Number	20	20	20	20
Mean age +/- SD	43.1 +/- 10.9	54.5 +/- 12.5	44.9 +/- 6.9	44.1 +/- 14.3
Sex F:M	10:10	13:8	11:9	12:8
Ethnicity (%)				
Caucasian	20 (100)	11 (55)	20 (100)	18 (90)
Afro-Caribbean	0 (0)	5 (25)	0 (0)	1 (5)
Asian	0 (0)	4 (20)	0 (0)	1 (5)
Phenotype (%)			NA	NA
Isolated TM	4 (20)	10 (50)		
TM + ON	10 (50)	4 (20)		
TM + BS/BR	5 (25)	4 (20)		
TM + BS/BR + ON	1 (5)	2 (10)		
Median disease duration in months (range)	40.1 (8.5 – 239.9)	141.5 (8.5 – 297.7)	147.1 (10.4 – 252.1)	NA
No. relapse/pt	2	3	3	NA
No. myelitis/pt	1.1	2.3	NA	NA

Figure 1. Cervical cord segmentation




Figure 2. Grey matter and lesion segmentation





Figure 3. FA map with segmented cord in native space



GROUP COMPARISON & CLINICAL RELEVANCE

Figure 4. Within-group differences based on lesion status

Grey line dotted line in each modality represents the healthy volunteer mean





Figure 5. (A) Relationship between mean cross-sectional area and disability in all disease groups, (B) Mean corticospinal tract FA and disability in all disease groups, and (C) Mean spinothalamic tract FA and pain score in those with neuropathic pain



CONCLUSION

MOGAD may predominantly affect the grey matter. AQP4-Ab disease shows the most severely affected cord, localised to lesional areas. The MRI metrics used in this study do not differentiate these conditions but have clinical relevance in their association with disability and pain scores, independent of disease type.

REFERENCES & DISCLOSURES

References: Chien, C., Brandt, A., Schmidt, F., Bellmann-Strobl, J., Ruprecht, K., Paul, F., & Scheel, M. (2016). MRI-Based Methods for Spinal Cord Atrophy Evaluation: A Comparison of Cervical Cord Cross-Sectional Area, Cervical Cord Volume, and Full Spinal Cord Volume in Patients with Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. *American Journal of Neuroradiology*, 39(7), 1362-1368. doi:10.3174/ajnr.a5665
Cassery, C., Seyman, E., Alcalde-Leon, P., Guenette, M., Lyons, C., Sankar, S., Svendrovski, A., Baral, S. and Oh, J. (2018). Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta-Analysis. *Journal of Neuroimaging*, 28(6), pp.556-586.
M. Jenkinson, C.F. Beckmann, T.E. Behrens, M.W. Woolrich, S.M. Smith. FSL. *NeuroImage*, 62:782-90, 2012
De Leener, B., Lévy, S., Dupont, S., Fonov, V., Stikov, N., Louis Collins, D., Callot, V. and Cohen-Adad, J. (2017). SCT: Spinal Cord Toolbox, an open-source software for processing spinal cord MRI data. *NeuroImage*, 145, pp.24-43.

Disclosures: R. Mariano is undertaking graduate studies funded by the Rhodes Trust. S. Messina has received travel grants from Biogen, Novartis, Bayer, Merck, Almirall and honorarium for advisory work from Biogen. A. Roca-Fernandez has no disclosures. A. Cavey has no disclosures. R. Everett has no disclosures. S. Reeve has no disclosures. M. Leite reported receiving speaking honoraria from Biogen Idec, and receiving travel grants from Novartis. Y. Kong is supported by The Chinese Academy of Sciences and The National Nature Science Foundation of China. J. Palace is partly funded by highly specialised services to run a national congenital myasthenia service and a neuromyelitis service. She has received support for scientific meetings and honorariums for advisory work and grants from Merck Serono, Novartis, Biogen Idec, Teva, Abide and Bayer Schering. Her hospital trust received funds for her role as clinical lead for the RSS, and she has received grants from the MS Society and Guthy Jackson Foundation for research studies.